← Back
Research Paper Volume 13, Issue 16 pp 20661—20683

METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas

class="figure-viewer-img"

Figure 6. Six immune-related gene sets were enriched by GSEA.